Kyto Technology Life Science, Inc. (KBPH) SEC Filing 8-K Material Event for the period ending Friday, February 4, 2022

Kyto Biopharma Inc

CIK: 1164888 Ticker: KBPH

View differences made from one to another to evaluate Kyto Biopharma Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kyto Biopharma Inc.


Assess how Kyto Biopharma Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kyto Biopharma Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: KBPH
CIK: 1164888
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-003537
Submitted to the SEC: Wed Feb 09 2022 8:48:47 AM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Friday, February 4, 2022
Industry: Pharmaceutical Preparations
  1. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: